Eli Lilly & Co. (LLY) Reports New Verzenio Phase 3 monarchE Trial Data Published in the Annals of Oncology

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/11/2026

1. ORCL
2. SPY
3. CHWY
4. SPCX
5. USO
6. NAVN
7. HUMA
8. cASY
9. CME
10. TSLA

Go back to Eli Lilly & Co. (LLY) Reports New Verzenio Phase 3 monarchE Trial Data Published in the Annals of Oncology

Additional Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Published in the Annals of Oncology

October 28, 2021 4:00 PM EDT

INDIANAPOLIS, Oct. 28, 2021 /PRNewswire/ -- Today, overall survival (OS) data from Eli Lilly and Company's (NYSE: LLY) Verzenio® (abemaciclib) Phase 3 monarchE study were published in a Letter to the Editor in the Annals of Oncology. These OS data, while immature, have been published to address questions regarding the recent approval by the U.S. Food and Drug... More